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We constructed recombinant viruses expressing enhanced green fluorescent protein (EGFP) or firefly luciferase from cDNA clones of the
canine distemper virus (CDV) (a Japanese field isolate, Yanaka strain). Using these viruses, we examined susceptibilities of different cell lines to
CDV infection. The results revealed that the recombinant CDVs can infect a broad range of cell lines. Infectivity inhibition assay using a
monoclonal antibody specific to the human SLAM molecule indicated that the infection of B95a cells with these recombinant CDVs is mainly
mediated by SLAM but the infection of 293 cell lines with CDV is not, implying the presence of one or more alternative receptors for CDV in non-
lymphoid tissue. Infection of 293 cells with the recombinant CDV was inhibited by soluble heparin, and the recombinant virus bound to
immobilized heparin. Both F and H proteins of CDV could bind to immobilized heparin. These results suggest that heparin-like molecules are
involved in CDV infection.
© 2006 Elsevier Inc. All rights reserved.Keywords: Canine distemper virus; Host range; Receptor; Heparin; GlycosaminoglycanIntroduction
Canine distemper virus (CDV) possesses a non-segmented
single stranded RNA genome with negative polarity and
belongs to the genus Morbillivirus within the family Para-
myxoviridae. CDV infection induces such symptoms as fever,
diarrhea, immunosuppression and encephalitis in dogs and
other canids along with high mortality rates. For many decades,
animals susceptible to CDV infection had been thought to be
limited to those in the family Canidae. However, CDV
infections in seals, lions, tigers and leopards were recently
reported (Appel et al., 1994; Grachev et al., 1989; Roelke-
Parker et al., 1996). Moreover, CDV infection is prevalent in
domestic dogs which have already been vaccinated (Blixenk-
rone-Moller et al., 1993; Gemma et al., 1996; Kai et al., 1993;
Maes et al., 2003). Since recent isolates were serologically
distinct from the vaccine strain (Gemma et al., 1996), it is⁎ Corresponding author. Fax: +81 3 5449 5379.
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doi:10.1016/j.virol.2006.09.018suspected that vaccination with the current vaccine strain can no
longer completely protect dogs from CDV infection.
It has been reported that SLAM (CD150) is a cellular
receptor for morbilliviruses including CDV (Tatsuo et al., 2000;
Tatsuo et al., 2001). However, most of the reverse genetics
systems for morbilliviruses are based on their vaccine strains
which have been adapted to Vero cells (Baron and Barrett, 1997;
Gassen et al., 2000; Parks et al., 2002; von Messling et al.,
2001). SLAM molecules are expressed only on the cells of the
immune system (immature thymocytes, activated lymphocytes,
activated monocytes and mature dendritic cells), and not on
Vero cells (Seki et al., 2003). It is not easy to isolate wild-type
CDVs using Vero cells (Seki et al., 2003). Furthermore, the
Vero-adapted CDV isolates have exhibited biased hypermuta-
tions and have been attenuated (Nielsen et al., 2003). Recently,
we have succeeded in recovering an infectious CDV from a
cDNA clone of a field isolate (Yanaka strain) (Kai et al., 2000).
The Yanaka strain of CDV, which was obtained from a dog
clinically diagnosed with distemper, was isolated and main-
tained in B95a cells (Gemma et al., 1996) which are derived
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SLAM molecules on their surface. Although several reverse
genetics systems have been reported for CDV Onderstepoort
strain (Gassen et al., 2000; Parks et al., 2002; von Messling et
al., 2001) and Vero-adapted A75/17 strain (Plattet et al., 2004),
these viruses were maintained in Vero cells and may be
inappropriate to be used for the investigation of CDV host
range.
Glycosaminoglycans (GAGs) are linear (unbranched) het-
eropolysaccharides consisting of repeated disaccharide units
that are variably N- and O-sulfated (Jackson et al., 1991).
GAGs are covalently attached to the protein cores of
proteoglycans, which are ubiquitously expressed as integral
membrane proteins, glycerol phosphatidyl inositol-linked
membrane proteins and proteins of the extracellular matrix. In
vivo, GAGs bind to a diverse group of growth factors,
chemokines, enzymes, and matrix components (Jackson et al.,
1991). In certain viruses, including human herpes simplex virus
(WuDunn and Spear, 1989), human immunodeficiency virus
type I (Patel et al., 1993), vaccinia virus (Chung et al., 1998),
adenovirus types 5 and 2 (Dechecchi et al., 2000), hepatitis C
virus (Barth et al., 2003), respiratory syncytial virus (Krusat and
Streckert, 1997) and human parainfluenza type 3 (Bose and
Banerjee, 2002), heparan sulfate is involved in the process of
viral entry. The latter two viruses are the members of the family
Paramyxoviridae to which CDV belongs.
In the present study, we report the construction of
recombinant CDVs harboring an enhanced green fluorescent
protein gene or a firefly luciferase gene. Using these
recombinant CDVs, we investigated the susceptibilities of
various cells to infection with the recombinant CDV infection
and examined cellular surface molecules implicated in CDV
infection.
Results
Recovery of recombinant CDVs expressing EGFP or firefly
luciferase
The plasmid pCDV containing the full-length cDNA of
CDV was manipulated to contain the unique restriction enzyme
sites in the non-coding regions between adjacent genes of the
genome. The FseI site, which was inserted immediately
downstream of the CDV N gene, was chosen to introduce the
additional genes. The coding regions of EGFP and luciferase
genes were attached to transcription signal (transcription
termination/polyadenylation signal of N gene and transcription
start signal of H gene) units and cloned into the FseI site of
pCDV. The resulting plasmids, pCDV-EGFP and pCDV-Luc,
were co-transfected into 293 cells preinfected with the
recombinant vaccinia virus MVA-T7 expressing phage T7
RNA polymerase, together with supporting plasmids which
supply the N, P and L proteins of rinderpest virus. The reason
why we used a set of supporting plasmids of rinderpest virus is
that our supporting plasmids of CDV did not work in our hands.
The cells were incubated for 3 days followed by co-cultivation
with B95a cells. After incubation of several days, syncytiainduced by the recombinant CDVs were observed. The sizes of
syncytia produced by three recombinant viruses were similar
(Fig. 1C). The expression of EGFP in rCDV-EGFP-infected
cells was verified under the confocal microscopy (Fig. 1C), and
that of luciferase in rCDV-Luc-infected cells was confirmed by
the measurement of luciferase activity in cell lysates (data not
shown; see also Table 1). Growth of the rCDV-EGFP and
rCDV-Luc was slightly slower than that of the rCDV, however,
the maximum titers were similar to that of the rCDV (data not
shown).
Host range of CDV characterized using recombinant viruses
Using rCDV-EGFP, susceptibilities of several primary tissue
cultures and cell lines to CDV infection were analyzed. Cells of
canine origin such as primary-cultured dog embryo brain cells,
stimulated PBMC, 3132 cells and MDCK cells, and cells
derived from other species, namely, CRFK cells (cat),
stimulated phocine PBMC, stimulated lion PBMC, 293 cells
(human), HeLa cells (human), Vero cells (African green
monkey), COS-7 cells (African green monkey), NIH-3T3
cells (mouse), CPK cells (pig), MDBK cells (cattle), RK13
cells (rabbit) and BHK-21 cells (baby hamster), were infected
with rCDV-EGFP at an MOI of 2 TCID50/cell (determined in
B95a cells). Forty hours after infection, the cells were harvested
and the expression of EGFP was analyzed by flow cytometry
(the results are summarized in Table 1). All of the tested cells
derived from dog or non-dog species were shown to be
susceptible to infection by the recombinant CDV, although the
susceptibilities of individual cell lines were variable. Unexpect-
edly, NIH-3T3, a mouse fibroblast cell line, was found to be
susceptible to rCDV-EGFP infection, while it has been reported
that the Onderstepoort strain, a vaccine strain of CDV, cannot
infect these cells (Loffler et al., 1997). The infectivities of
rCDV-EGFP for cell lines were generally higher than those for
primary cells except BHK-21 cells.
We also infected these cells with rCDV-Luc at the same
MOI, and luciferase activities in these cells were measured
(Table 1). Consistent with the results of rCDV-EGFP infection,
all of the cell lines infected with rCDV-Luc showed luciferase
activities. Relative luciferase activities per infected cell were
calculated for different cell types using data obtained from
rCDV-EGFP and rCDV-Luc infections, revealing that the
relative activities varied among these cells ranging from 3.42
RLU/cell (HeLa cells) to 145 RLU/cell (BHK-21 cells).
Inhibition of rCDV-EGFP infection by monoclonal antibodies
Field isolates of CDV use SLAM (also known as CD150)
expressed on B95a cells as their receptor, as measles virus does
(Tatsuo et al., 2001). To investigate whether the Yanaka strain of
CDValso uses SLAM as its receptor, B95a cells were incubated
with a monoclonal antibody (clone IPO-3) specific against
human SLAM prior to infection with rCDV-EGFP. In the
absence of the antibodies, approximately 90% of B95a cells
were EGFP-positive (Fig. 2A; panel a). The presence of an anti-
SLAM antibody significantly inhibited the infection of B95a
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Table 1
Comparison of rCDV-EGFP infectivities and luciferase activities in infected
cells with rCDV-Luc
% infectivity Luciferase activity
(RLU/104 cells)
Relative activity
(RLU/infected cell)
HeLa 38.0 1.3×106 3.4
293 40.0 1.9×107 47.5
Vero 8.4 1.3×106 15.5
MDCK 20.3 2.2×106 10.8
CRFK 50.5 7.7×106 15.2
RK-13 22.6 3.4×106 15.0
BHK-21 2.0 2.9×106 145.0
MDBK 21.4 2.6×106 12.1
CPK 15.3 1.9×106 12.4
NIH-3T3 17.5 7.2×105 4.1
COS-7 32.8 4.9×106 14.9
B95a 92.6 1.9×107 20.5
3132 32.2 2.0×107 62.1
DEB 2.5 2.0×106 80.0
Dog PBMC 5.0 4.5×106 90.0
Phocine PBMC 4.4 2.6×106 59.1
Lion PBMC 1.8 5.3×105 29.4
Cells were infected with rCDV-EGFP or rCDV-Luc at an MOI of 2 TCID50/cell
(determined in B95a cells) and analyzed at 40 h.p.i.
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panel c), whereas the infection was not inhibited by a
monoclonal antibody (M177) against human CD46 (a receptor
for the Edmonston strain of measles virus (MV) (Fig. 2A; panel
b)). Thus, it was revealed that the Yanaka strain of CDV also
uses the SLAMmolecule expressed on B95a cells as its receptor
like other field isolates of CDV, MV and rinderpest virus. As
SLAM is believed to be expressed only on cells of limited types
in vivo, such as lymphoid cells and dendritic cells, the infection
of other cell types as described above means SLAM is not the
only receptor for CDV. Actually, the infection of 293 cells with
rCDV-EGFP was blocked by neither anti-SLAM antibody (Fig.
2B; panel c) nor anti-CD46 antibody (Fig. 2B; panel b). The
negative inhibition of our field isolate strain of CDV by anti-
CD46 antibody is consistent with the results for a vaccine strain
(Loffler et al., 1997). Thus, it is suspected that the entry of CDV
into 293 cells and other non-lymphoid tissues is mediated by
one or more unknown surface molecules.
Inhibition of rCDV-EGFP infection by soluble GAGs
CDV can infect a large variety of cells regardless of the
expression of the SLAM molecules on their surface. Since
infections of cultured cells with heparan sulfate-binding
viruses are blocked by heparin, we investigated the effect of
heparin treatment on CDV infection. rCDV-EGFP was
incubated with heparin at a concentration of 1 μg/ml prior
to the inoculation to B95a cells or 293 cells, and then the
EGFP-positive cells were analyzed by flow cytometry.Fig. 1. (A) Strategy for construction of the full-genomic cDNA clone of CDV. (B) Co
structural proteins of CDV are shown as filled boxes. Additional sequences of T7 pr
which contain CDV GE signal, GS signal and EGFP or Luc ORF franked by FseI res
Syncytia formation in B95a cells infected with the rCDV, rCDV-Luc or rCDV-EGFP.
detect the expression of EGFP.Treatment of rCDV-EGFP with heparin had little effect on
the infection of B95a cells (Fig. 2A; panel d), although a
slight decrease in infectivity (from 88% (mock-treated) to
81% (heparin-treated)) was apparent (Fig. 2A; panels a and
d). When SLAM-dependent infection was inhibited by the
anti-SLAM antibody, the inhibitory effect of heparin was
more pronounced (26% for anti-SLAM antibody treatment vs.
15% for anti-SLAM antibody plus heparin treatment) (Fig.
2A; panels c and e). On the other hand, infection of 293 cells
with rCDV-EGFP was dramatically inhibited in the presence
of heparin (Fig. 2B; panel d). These results suggest that
heparin-like molecules are involved in infection of rCDV-
EGFP via SLAM-independent pathway. The major GAGs
found on most cells are heparan sulfate and the chondroitin
sulfates (Kjellen and Lindahl, 1991). Thus, rCDV-EGFP was
also treated with heparan sulfate, chondroitin sulfate A, B
(also known as dermatan sulfate) or C prior to inoculation to
293 cells. Consistent with the results shown in Fig. 2A,
treatment of rCDV-EGFP with heparin inhibited the infection
of 293 cells in a dose-dependent manner (Fig. 3A). Treatment
of rCDV-EGFP with heparan sulfate also inhibited the
infection of 293 cells (Fig. 3C), however, the effect was
smaller than that of heparin. Chondroitin sulfate A and C did
not significantly inhibit the infection of 293 cells with rCDV-
EGFP (Figs. 3D and F), although a slight inhibition was
observed at a high concentration. In the case of chondroitin
sulfate B, infectivity was reduced by the treatment and the
inhibition rate was similar to that by heparan sulfate (Fig.
3E). On the other hand, treatment of rCDV-EGFP with
heparin did not inhibit the infection of B95a cells (Fig. 3B)
consistent with the results shown in Fig. 2A. These results
indicate that heparin-like molecules are involved in CDV
infection of SLAM-negative cells to more extent than that of
SLAM-positive cells. Since rCDV-EGFP is a recombinant
virus from cDNA, it still remains possible that the results
obtained above do not reflect the native characteristics of
CDV. To confirm the involvement of heparin-like molecules
in the entry of the parental CDV strain, the Yanaka strain of
CDV was treated with heparin before inoculation to 293 cells
and the infectivity was determined by the use of a
monoclonal antibody specific to the H protein of CDV. The
results were consistent with the results obtained with rCDV-
EGFP (data not shown). Therefore, those characteristics
mentioned above were not acquired through a recovery of
rCDV-EGFP.
Heparin-binding ability of rCDV-EGFP and its glycoproteins
To investigate whether CDV particles directly bind to
heparin-like molecules, concentrated supernatant of rCDV-
EGFP-infected B95a cells was subjected to heparin affinitynstruction of recombinant rCDV-EGFP and rCDV-Luc. Coding regions for viral
omoter, terminator and ribozyme are shown as open boxes. Artificial fragments
triction enzyme sites (underlined) were introduced into pCDV (V−) plasmid. (C)
rCDV-EGFP-infected B95a cells were also analyzed by confocal microscopy to
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with the rCDV-EGFP, and the bound materials were eluted with
high concentrations of salt. The presence of virus was
determined by western blot analysis using an anti-N monoclonal
antibody. Despite the finding that no virion was recovered from
BSA-agarose (Fig. 4A, lane 5), the rCDV-EGFP virions were
eluted from heparin-agarose (Fig. 4A, lane 3). Thus, the
recombinant CDV directly binds to heparin at a physiological
salt concentration.
To investigate which CDV glycoprotein (F or H) binds to
heparin, 293 cells were independently transfected with expres-
sion plasmids for CDV F and H. Proteins were metabolically
labeled by 35S-methionine and cysteine, and the cell lysates
were subjected to heparin affinity chromatography, followed by
immunoprecipitation using specific antibodies against F and H
proteins (Fig. 4B). Both of the F and H proteins were found to
bind to the heparin-agarose. However, the H protein was only
faintly detected in the elution fractions (Fig. 4B, right panel),
whereas the F protein gave strong signals (Fig. 4B, left panel).
Because of the nature of the experiments, we could not compare
the binding strength between the F and H proteins. Never-
theless, our results strongly suggest that not only H protein but
also F protein of CDV is involved in the attachment to cell
surface molecules.
Discussion
Reverse genetics system for CDV was recently established
(Gassen et al., 2000; Kai et al., 2000; Parks et al., 2002; von
Messling et al., 2001). Recombinant CDVs established by other
groups are based on a vaccine strain (the Onderstepoort strain;
isolated and passaged in Vero cells) or a Vero-adapted field
isolate (Plattet et al., 2004) while ours are based on a recent field
isolate (the Yanaka strain; isolated in B95a cells from an
affected dog in Japan in 1994). In measles virus (MV), it has
been reported that MV propagated in Vero cells loses its
pathogenicity, while MV propagated in B95a cells maintains
virulence in vivo (Parks et al., 2002). It has also been reported
that field isolates of MV passaged in B cell lines use their entry
receptors different from that used by a vaccine strain passaged
in Vero cells (Bartz et al., 1998). Therefore, it is important to
establish a reverse genetics system based on field isolates
especially when investigating the native characteristics of CDV
such as its host cell specificity.
In the present study, we used a V-knockdown version of
cDNA clone of CDV to generate recombinant viruses
expressing foreign genes. V protein of measles virus has been
reported to be non-essential in vitro but act as a virulent factor
in vivo (Patterson et al., 2000; Tober et al., 1998; von Messling
et al., 2006), probably due to its ability to counteract host's
interferon system (Horvath, 2004). The purpose of this study is
not only to analyze the characteristics of CDV but also to obtain
basic information for production of multivalent vaccines and
viral vectors based on CDV. For the use of such recombinant
CDVs in vivo, pathogenicity of the vector itself should be as
little as possible. Therefore, for expressing foreign genes, we
constructed recombinant CDVs in which the V proteinproduction is abrogated. The parental strain of CDV and the
V(−) recombinant CDV grew similarly in vitro (data not
shown), and it seems unlikely that knockdown of V results in
altered host cell specificity in cell culture.
In this study, using recombinant CDVs expressing EGFP or
firefly luciferase, we investigated susceptibilities of cells
derived from non-dog species to CDV infection using the
recombinant viruses. A broad range of cells was shown to be
susceptible to CDV infection. It has been reported that the
Onderstepoort strain of CDV can infect various cell lines
(Loffler et al., 1997). rCDV-EGFP in the present study was able
to infect the NIH-3T3 cell line, although it has been reported
that the Onderstepoort strain cannot infect this cell line (Loffler
et al., 1997). This is not surprising because some strains of CDV
can be propagated in mouse brain. In this study, we found no
cells that are completely resistant to CDV infection.
Using the recombinant rCDV-Luc, we determined levels of
CDV transcription in infected cells (Table 1). Since luciferase is
a very sensitive marker, rCDV-Luc facilitates detection of
infection at low levels. Actually, we detected considerably high
luciferase activities in cells which were associated with low
rCDV-EGFP infectivities. Surprisingly, the luciferase activity in
BHK-21 cells was almost equivalent to those in other epithelial
cell lines, while the rCDV-EGFP infectivity in BHK-21 cells
was much lower than those in other cell lines. The relative
luciferase activity per single infected BHK-21 cell calculated by
dividing the luciferase activity by the infectivity was higher than
those of other cell lines, including B95a cells which are highly
susceptible to CDV infection. It might be possible that the
transcription of CDV is upregulated in BHK-21 cells. Alter-
native possibility is that the duration of mRNA or translation
efficiency is different between EGFP and luciferase within
BHK-21 cells, although the 5′- and 3′-non-coding regions
within those recombinant viruses are the same. It is also
possible that duration of one of these proteins is somewhat
different in BHK-21 cells compared to that in other types of
cells.
It has been reported that field isolates of CDVuse SLAM as a
receptor (Lan et al., 2005; Seki et al., 2003; Tatsuo et al., 2001).
In this study, infection of B95a cells with rCDV-EGFP was
inhibited by treatment with an anti-SLAM monoclonal anti-
body. However, it is also known that SLAM is expressed at high
levels only on lymphoid cells and dendritic cells, a fact that
seems to be inconsistent with the infection of other cells by
CDV. The question of whether CDV infects primarily SLAM+
cells in vivo remains to be answered. Infection of 293 cells with
rCDV-EGFP was not inhibited by the aforementioned antibody
(Fig. 4) because of the lack of SLAM expression on 293 cells.
Thus, CDV seems to have the intrinsic capacity to use more
than one receptor. To investigate whether CDV can utilize the
CD46 molecule as an alternative receptor like measles virus
does, we performed an infection inhibition assay based on 293
cells using an anti-human CD46 monoclonal antibody. This
antibody did not inhibit infection of 293 cells with CDV (Fig.
2B; panel b). So far, no CDV strain that uses CD46 as a receptor
has been reported. Therefore, there may be one or more cellular
receptors for CDV in addition to SLAM, and such unknown
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range of CDV infection.
Since a broad range of cells was susceptible to CDV
infection, we tested whether heparin-like molecules are
involved in CDV infection. Infection of 293 cells with
rCDV-EGFP was inhibited in the presence of heparin. It was
also the case with heparan sulfate and chondroitin sulfate B,Fig. 2. Effect of monoclonal antibodies against CD46 or SLAM or heparin on rCDV
CD46 or SLAM prior to infection with rCDV-EGFP. Meanwhile, rCDV-EGFP was
mock-treated. Panel b, treated with anti-CD46 antibody (clone M177). Panel c, treated
treated with anti-SLAM antibody plus heparin. EGFP-positive cells were analyzed by
cells.although the effects were less pronounced than that of
heparin. It has been reported that infection with relevant MV
was not inhibited by heparin (Feldman et al., 2000). However,
in that report, the authors used Vero cells which express
CD46, the high-affinity receptor for laboratory strains of MV
(Feldman et al., 2000). Therefore, the effect of soluble
heparin on the attachment of MV might be hidden. In our-EGFP infection. Cells were treated with monoclonal antibodies against either
treated with heparin prior to inoculation. (A) B95a cells. (B) 293 cells. Panel a,
with anti-SLAM antibody (clone IPO-3). Panel d, treated with heparin. Panel e,
flow cytometry. Thin line: mock-infected cells. Thick line: rCDV-EGFP-infected
Fig. 2 (continued).
330 K. Fujita et al. / Virology 359 (2007) 324–335experiment, infection of B95a cells with rCDV-EGFP was not
significantly inhibited by heparin, however, the inhibitory
effect of heparin was pronounced when the B95a cells were
treated with an anti-SLAM antibody to inhibit the SLAM-
dependent infection. These results support the idea that the
infection of B95a cells was mainly mediated by the high-
affinity receptor SLAM, and the contribution of heparin-like
molecules might be low. However, if the cells do not express
high-affinity receptor, the virus manages to infect those cells
via other pathway in which heparin-like molecules are
involved. Increasing evidences suggest that, besides SLAM
and CD46, there are yet unidentified receptor for MV since
many cells are infected with MV even when these molecules
are absent or blocked (Andres et al., 2003; Hashimoto et al.,
2002; Ishida et al., 2004; Shingai et al., 2003; Takeuchi et al.,
2003). Further studies on roles of heparin-like molecules in
MV infection are now under investigation.
In this study, treatment of rCDV-EGFP with heparin or other
GAGs did not completely block the infection with the rCDV-
EGFP. These results suggest that other molecules than heparin-
like molecules are also involved in the attachment process. It is
thought that most of the heparan sulfate-binding proteins use
heparan sulfate as a regulator of ligand-dependent activation of
primary signaling receptors at the cell surface (Carey, 1997).
Thus, it is possible that cell surface GAGs concentrate the virionon the two-dimensional surface of the plasma membrane and the
binding to heparin-like molecules increases the ability to bind to
the low affinity receptor present in most cell species. Therefore,
the binding to heparin-like molecules itself might not cause viral
entry, and the function of these molecules may support the
binding of virus to the low affinity or quantity receptor.
Interestingly, it was recently reported that DC-SIGN expressed
on dendritic cells is an attachment receptor for MV (de Witte et
al., 2006). DC-SIGN itself does not support virus entry,
however, it enhances CD46- and SLAM-mediated infection. It
is possible that similar phenomenon occurs between heparin-like
molecules with SLAM or other unknown receptor(s).
The reason why chondroitin sulfate B inhibited the
infection with the rCDV-EGFP to a greater extent compared
to chondroitin sulfate A or C (Fig. 1) remains to be
elucidated. However, similar data have been obtained for
other heparin-binding viruses (Byrnes and Griffin, 1998;
Jackson et al., 1996; Summerford and Samulski, 1998). One
possible explanation is the similarity of chondroitin sulfate B
to heparan sulfate and heparin. Chondroitin sulfate B
(dermatan sulfate) is the only chondroitin sulfate that contains
the IdoA monosaccharides that are found in heparan sulfate
and heparin (Rostand and Esko, 1997). The requirement of
IdoA in glycosaminoglycans for infection with respiratory
syncytial virus has been reported (Hallak et al., 2000), and it
Fig. 3. Inhibition of rCDV-EGFP infection by soluble GAGs. rCDV-EGFP was treated with heparin (A), heparan sulfate (C), chondroitin sulfate A (D), chondroitin
sulfate B (E) or chondroitin sulfate C (F) at different concentrations for 1 h and inoculated to 293 cells. The virus was also treated with heparin and inoculated to B95a
cells in the same manner (B). The infectivities were measured by flow cytometry. Relative infectivities to mock-treated samples are shown.
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of IdoA units in GAGs.
We also demonstrated that both of the F and H proteins of
CDV bind to heparin. It has been reported that human
respiratory syncytial virus can bind to heparan sulfate with
glycoprotein G and glycoprotein F (Feldman et al., 2000;
Karger et al., 2001). We did not find the linear heparin-binding
motif in the CDV H gene by sequence analysis (data not
shown). In the F protein, there is a basic amino acid-rich region
near the cleavage site, and it is possible that the F protein bindsto heparin via this region. It has been generally considered that,
between the glycoproteins of the morbilliviruses, only the H
protein is involved in virus attachment to cells. The results
obtained in the present study indicate that not only the H but
also the F protein may be involved in the virus attachment of
morbilliviruses.
In foot-and-mouth disease virus, Sindbis virus and tick-
borne encephalitis virus, it has been reported that the acquisition
of the ability to bind to heparan sulfate correlates to the reduced
pathogenicity in vivo (Klimstra et al., 1998; Mandl et al., 2001;
Fig. 4. Heparin affinity chromatography of rCDV-EGFP and its glycoproteins.
(A) Heparin affinity chromatography of rCDV-EGFP. Lane 1: positive control
(purified rCDV-EGFP), lane 2: final wash fraction from heparin-agarose, lane 3:
elution fraction from heparin-agarose, lane 4: final wash fraction from BSA-
agarose, lane 5: elution fraction from BSA-agarose. The fractions were analyzed
on SDS-PAGE, and the presence of CDVwas detected by western blotting using
a monoclonal antibody against N protein of CDV. (B) Heparin affinity
chromatography using cell extract of 293 cells transfected with the expression
plasmids encoding either F (left panel) or H gene (right panel) of CDV. Proteins
were eluted by increasing concentrations of NaCl in a stepwise manner.
Individual fractions were immunoprecipitated with monoclonal antibodies
against F or H protein of CDV. Lane 1: cell lysate of 293 cells transfected with
the expressing plasmid of corresponding gene of CDV, lane 2: final wash
fraction, lanes 3–6: elution fractions. NaCl concentrations used for elution are
indicated on the top of the lanes.
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binding activity is advantageous for virus in cell culture, but the
acquisition of the ability to bind to a new receptor can also
ameliorate or even abrogate disease by sequestering the virus to
sites that are not favorable for replication. It has been reported
that different strains in the same virus have a different affinity to
heparin, and the adaptation of virus in cell culture selects for the
use of heparan sulfate as an attachment receptor (Klimstra et al.,
1998; Sa-Carvalho et al., 1997). In measles virus (MV), it has
been shown that MV propagated in Vero cells lost its
pathogenicity, while MV propagated in B95a cells maintained
its virulence in vivo (Kobune et al., 1990). In addition, it was
also reported that field isolates of MV passaged in B cell lines
use different receptors for viral entry than a vaccine strain
passaged in Vero cells (Bartz et al., 1998). The Yanaka strain of
CDV was isolated and passaged in B95a cells, but this strain is
apathogenic to dogs. It is not known whether the adaptation of
CDV to a marmoset cell lines correlates with the loss of
pathogenicity. Establishment of suitable canine cell lines is
awaited. During the preparation of this manuscript, Baron
published a paper reporting that cell culture-adapted strains of
rinderpest virus, which is in the same genus as canine distemper
virus, use heparan sulfate as a receptor (Baron, 2005). This
study and ours reveal that morbilliviruses may have an ability to
use or to be adapted to use heparin-like molecules in the process
of viral entry.Materials and methods
Virus and cells
Viruses were propagated in B95a cells (Kobune et al., 1990)
as described previously. 293 cells were grown in Dulbecco's
modified minimum essential medium (DMEM) containing 10%
fetal calf serum (FCS) and antibiotics. B95a cells and 3132 cells
(canine lymphoma cell line of B cell origin) were grown in
RPMI containing 5% FCS. Primary-cultured cells from a dog
embryo (DEB), MDCK (canine kidney), CRFK (feline kidney),
Vero (monkey kidney), HeLa (human uterus), COS-7 (monkey
kidney), 293 (human kidney), NIH-3T3 (mouse fibroblast),
CPK (pig kidney), MDBK (cattle kidney), RK-13 (rabbit
kidney), and BHK-21 (hamster kidney) cells were grown in
DMEM containing 10% FCS and appropriate concentration of
antibiotics. PBMC from a dog, a seal and a lion were isolated by
density gradient centrifugation using Ficoll Plaque reagent
(Pharmacia) and stimulated by 5 μg/ml of ConA in RPMI 1640
medium containing 10% FCS and 100 U/ml of recombinant
human IL-2 for 3 days and then cultivated in RPMI 1640
medium containing 10% FCS and 100 U/ml of recombinant
human IL-2.
DNA manipulations
The strategy for the construction of cDNA clones of CDV is
summarized in Fig. 1A. At first, 3′ and 5′ non-coding sequences
of the Yanaka strain were cloned into pMDB1 plasmid
(generously provided by M. Baron). To facilitate the subsequent
subcloning, nucleotides between 81 and 86 of the CDV genome
(ACAAGG) were mutated to BsiWI site (CGTACG), and
nucleotides between 15,609 and 15,616 (CTGCTATTCA) were
mutated to NotI site (GCGGCCGC). Primer pairs, 5′-GACGT
ACGTCAGGGTTCAGACCTACCAGTATGGCTAGCCTT-
CTTAAG-3′ and 5′-ACCTCGAGGCCGGCCTTAATTGA-
GTAGCTCTCT-3′, 5′-GCCTCGAGGTGTTACATCAGT-
CACCA-3′ and 5′-TATCTAGAGTTTAAACTTAAG-
CATGTGTGATACT-3′, 5′-ACTCTAGATAATCTATTA-
ACAGGTTCA-3′ and 5′-TAACGCGTTAGAGAATTTT-
GAAAAG-3 ′ , 5 ′ -TAACGCGTTAGTTCATGAAC-
TAAAACTC-3′ and 5′-GTGGTACCGCGATCGCTCAG-
AGTGATCTTACATA-3′, 5′-GCGGTACCACGTCTTACCT-
GATTGTTA-3′ and 5′-GAGTCGACTTAATTAACTATCA-
AGGTTTTGAACG-3′, 5′-AAGTCGACTCTCAATTGAACT-
TAAGGA-3′ and 5′-TGGCGGCCGCAGGGTTAGGATCCA-
GACC-3′ were used to amplify the genes for N, P, M, F, H and
L, respectively (unique restriction enzyme recognition sites
underlined). Amplified products were sequentially cloned into
the plasmid described above. Finally, sequences of BsiWI and
NotI recognition sites were mutated to the original sequences
to produce the plasmid pCDV.
A derivative of pCDV (pCDV V(−)) which harbors
mutations within editing site of V protein was made by site-
directed mutagenesis using primers 5′-GAGTGTGGACCCAT-
TAAGAAAGGCACAGGAGAGAG-3′ and 5′-CTCTCTC-
CTGTGCCTTTCTTAATGGGTCCACACTC-3′.
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amplified from pEGFP-N1 (Clontech) using the following
primers. 5′-TAAGGCCGGCCAAACTCATTATAAAAAACT-
TAGGGCTCAGGTAGTCCAACAATGGTGAGCAAGGGC-
GAGGA-3′ and 5′-TCGAGGCCGGCCTTACTTGTACA-
GCTCGTCCA-3′ (FseI site underlined). The PCR products
were cloned into pCR2.1 vector (Invitrogen), and sequences
were confirmed. Then, the plasmid was digested by endonu-
clease FseI and inserted into the FseI site of pCDV V(−)
(downstream of the N gene). Firefly luciferase gene was
amplified from pGL3-basic (Promega) using the following
primers. 5′-GAATGCTTCTAAACTCATTATAAAAAACT-
TAGGGCTCAGGTAGTCCAACAATGGAAGACGC-
CAAAAACA-3′ and 5′-GAATGCTTTACACGGCGAT-
CTTTCCGC-3′. The PCR product was cloned into pCR2.1
vector (Invitrogen) and sequences were confirmed. The plasmid
was digested by restriction enzyme BsmI, and the cutting ends
were polished with T4 DNA polymerase (Takara). The
fragments were ligated to FseI linker (5′-AGGGGC-
CGGCCCCT-3′; FseI site underlined) which had been annealed
and phosphorylated with T4 polynucleotide kinase (TOYOBO)
and digested by FseI. The fragment was cloned into FseI site of
pCDV V(−). The forward primers contain a transcription signal
unit of CDV, that is transcription termination signal of the N
gene, followed by intergenic trinucleotides, CTT, which are
conservative except that in H–L junction and L–trailer junction
and subsequently followed by transcription start signal of the H
gene. This construct allows the additional gene to express in the
form of an extra transcription unit. The resulting full-genome
plasmids carrying EGFP gene or luciferase gene were
designated as pCDV-EGFP or pCDV-Luc, respectively.
The expression plasmids for CDV F and H proteins were
constructed as follows. The coding region of F gene was
amplified using the following primers; 5′-CCGGAATTCT-
TAGGGTCCAGGACATAGCA-3′ and 5′-CCGGAATTC-
GACTACCTGAGCCCTAAGTT-3′. The PCR product was
phosphorylated by T4 polynucleotide kinase (Takara) and
inserted into XhoI site of pCAGGS vector (a gift from Dr. J.
Miyazaki, Osaka University, Osaka, Japan) (Niwa et al., 1991).
The coding region of H gene was amplified using the following
primers; 5′-CCGCTCGAGCAGGTAGTCCAACAATG-3′ and
5′-CCGCTCGAGGTATCATCATACTATCA-3′. The PCR pro-
duct was digested by EcoRI and inserted into EcoRI site of
pCAGGS. The resulting plasmids were designated as pCAG-F
and pCAG-H, respectively.
Recovery of recombinant CDVs
293 cells in 6-well culture dish were inoculated with
recombinant vaccinia virus encoding T7 RNA polymerase
(MVA-T7) for 1 h and then transfected with 1 μg of pCDV-
EGFP or pCDV-Luc, 1 μg of pKSN1 and 1 μg of pKSP and
0.3 μg of pGEML per well, which express N, P and L
protein of rinderpest virus (Baron and Barrett, 1997),
respectively, under the control of T7 promoter, using Fugene
6 (Roche) as a transfection reagent. After 3 days of
incubation, the cells were co-cultivated with B95a cells, amarmoset B lymphoblast cell line (Kobune et al., 1990) in
which CDV can replicate effectively (Kai et al., 1993), at a
concentration of 2×106 cells per well and further incubated
in RPMI (Sigma) containing 1.5% FCS until extensive
cytopathic effects appeared. The recovered CDVs were
designated as rCDV, rCDV-EGFP or rCDV-Luc from
plasmids pCDV, pCDV-EGFP or pCDV-Luc, respectively.
The cells were collected and lysed by 3 cycles of freezing
and thawing. After sonicated, samples were centrifuged at
3000 rpm to remove cell debris and stored as a crude virus
stock at −80 °C. The 50% tissue culture infective dose
(TCID50) was quantified using B95a cells by standard
methods.
Infection of various cell types with rCDV-EGFP
All types of cells were inoculated with rCDV-EGFP or
rCDV-Luc at an MOI of 2 TCID50/cell (determined in B95a
cells) and incubated for 40 h. The rCDV-EGFP-infected cells
were suspended in PBS containing 0.02% EDTA and washed
twice with sorter buffer (PBS containing 2% FCS and 0.1%
NaN3). Then, the flow cytometric analyses were performed
using FACScan (Becton Dickinson). The rCDV-Luc-infected
cells were suspended in PBS containing 0.02% EDTA, washed
twice with PBS and lysed in 50 μl of LCβ (Wako chemical).
Luciferase activity was measured by luminometer (Berthold)
using Picagene (Wako chemical) as a substrate.
Inhibition of recombinant CDV infection by antibodies
B95a and 293 cells (1×105 cells) in 24-well tissue plates
were incubated with a monoclonal antibody specific for
human SLAM (clone IPO-3) (KAMIYA industry) or human
CD46 (M177; kindly provided by Dr. Seya, Department of
Immunology, Osaka Medical Center for Cancer and Cardio-
vascular Diseases, Osaka, Japan) at a concentration of 5 μg/
ml and 10 μg/ml at 37 °C for 1 h, respectively. The cells were
inoculated with the rCDV-EGFP which was mock-treated or
pretreated with 1 μg/ml of heparin at an MOI of 2 TCID50/
cell (determined in B95a cells) in the presence of each
antibody at the same concentrations. After incubation for 1 h,
the inoculum was removed and maintenance medium contain-
ing each antibody at the same concentration was added. The
cells were further incubated for 40 h and analyzed by flow
cytometry.
Inhibition of infection by soluble GAGs
For infection inhibition assay, the rCDV-EGFP (1×105
TCID50) were incubated with heparin, heparan sulfate,
chondroitin sulfate A, B or C (all purchased from Sigma) at
various concentrations for 1 h at 37 °C and inoculated to 5×104
of B95a or 293 cells. After incubation for 1 h, the inoculum was
removed and the cells were washed twice with RPMI containing
2% FCS or DMEM containing 5% FCS and then further
incubated in the medium. Forty hours later, the cells were
harvested and analyzed by flow cytometry.
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293 cells in 10 cm culture dishes were transfected with either
pCAG-F or pCAG-H using Lipofectamine 2000 (Invitrogen) as
the transfection reagent. The cells were metabolically labeled
with 35S-methionine and cysteine (Pharmacia) at 36 h after
transfection for 14 h. Then, the cells were lysed in lysis buffer
(20 mM sodium phosphate (pH 7.4) containing 150 mM NaCl
and 1% Triton X-100).
Heparin affinity chromatography
For affinity chromatography of the rCDV-EGFP, the
supernatant of rCDV-EGFP-infected B95a cells was concen-
trated with a size exclusion (100K) membrane filter
(Amicon). After equilibration of heparin-agarose beads or
BSA-agarose beads (purchased from Sigma) in PBS,
concentrated virus supernatant was added to the beads and
incubated for 30 min at 4 °C. Beads were washed 7 times in
1 ml of PBS followed by elution in PBS containing 2 M
NaCl. The final wash and elution fractions were concentrated
using a 100K membrane filter (VIVASPIN; Sartorius) and
analyzed on SDS-PAGE followed by western blot analysis
using a monoclonal antibody against CDV N protein (clone
3) (Masuda et al., in press). For affinity chromatography of
CDV glycoproteins, heparin-agarose was equilibrated in lysis
buffer, and cell lysates were mixed with the beads, followed
by an incubation for 1 h at 4 °C. The beads were washed in
the lysis buffer (7 times; 1 ml each), and bound materials
were eluted with increasing concentrations of NaCl in a lysis
buffer (stepwise gradient: 250 mM, 500 mM, 1 M and 2 M).
The eluted fractions were immunoprecipitated with mono-
clonal antibodies against the F (clone a-8) (Hirayama et al.,
1991) or H protein (clone d-7) (Hirayama et al., 1991) of
CDV and analyzed on SDS-PAGE.
Acknowledgments
We thank to Dr. Thomas Barrett and Dr. Michel Baron for
providing MVA-T7, pMDB1, pKSN1, pKSP and pGEML and
for technical advices. We also thank Dr. Tsukasa Seya for
providing anti-CD46 antibody. This study was supported by
Grants-in-Aid from the Ministry of Education, Science, Culture,
and Sports, Japan and by a grant from the Program for
Promotion of Basic Research Activities for Innovative Bios-
ciences, Japan. K. Fujita and M. Yoneda were supported by
Research Fellowships from the Japan Society for the Promotion
of Science for Young Scientists.
References
Andres, O., Obojes, K., Kim, K.S., ter Meulen, V., Schneider-Schaulies, J.,
2003. CD46- and CD150-independent endothelial cell infection with wild-
type measles viruses. J. Gen. Virol. 84 (Pt. 5), 1189–1197.
Appel, M.J., Yates, R.A., Foley, G.L., Bernstein, J.J., Santinelli, S., Spelman, L.
H., Miller, L.D., Arp, L.H., Anderson, M., Barr, M., Pearce-Kelling, S.,
Summers, B., 1994. Canine distemper epizootic in lions, tigers, and leopards
in North America. J. Vet. Diagn. Invest. 6 (3), 277–288.Baron, M.D., 2005. Wild-type Rinderpest virus uses SLAM (CD150) as its
receptor. J. Gen. Virol. 86 (6), 1753–1757.
Baron, M.D., Barrett, T., 1997. Rescue of rinderpest virus from cloned cDNA.
J. Virol. 71 (2), 1265–1271.
Barth, H., Schafer, C., Adah, M.I., Zhang, F., Linhardt, R.J., Toyoda, H.,
Kinoshita-Toyoda, A., Toida, T., Van Kuppevelt, T.H., Depla, E., Von
Weizsacker, F., Blum, H.E., Baumert, T.F., 2003. Cellular binding of
hepatitis C virus envelope glycoprotein E2 requires cell surface heparan
sulfate. J. Biol. Chem. 278 (42), 41003–41012.
Bartz, R., Firsching, R., Rima, B., ter Meulen, V., Schneider-Schaulies, J., 1998.
Differential receptor usage by measles virus strains. J. Gen. Virol. 79 (Pt. 5),
1015–1025.
Blixenkrone-Moller, M., Svansson, V., Have, P., Orvell, C., Appel, M.,
Pedersen, I.R., Dietz, H.H., Henriksen, P., 1993. Studies on manifestations
of canine distemper virus infection in an urban dog population. Vet.
Microbiol. 37 (1–2), 163–173.
Bose, S., Banerjee, A.K., 2002. Role of heparan sulfate in human parainfluenza
virus type 3 infection. Virology 298 (1), 73–83.
Byrnes, A.P., Griffin, D.E., 1998. Binding of Sindbis virus to cell surface
heparan sulfate. J. Virol. 72 (9), 7349–7356.
Carey, D.J., 1997. Syndecans: multifunctional cell-surface co-receptors.
Biochem. J. 327 (1), 1–16.
Chung, C.S., Hsiao, J.C., Chang, Y.S., Chang, W., 1998. A27L protein mediates
vaccinia virus interaction with cell surface heparan sulfate. J. Virol. 72 (2),
1577–1585.
Dechecchi, M.C., Tamanini, A., Bonizzato, A., Cabrini, G., 2000. Heparan
sulfate glycosaminoglycans are involved in adenovirus type 5 and 2-host cell
interactions. Virology 268 (2), 382–390.
de Witte, L., Abt, M., Schneider-Schaulies, S., van Kooyk, Y., Geijtenbeek, T.
B., 2006. Measles virus targets DC-SIGN to enhance dendritic cell infection.
J. Virol. 80 (7), 3477–3486.
Feldman, S.A., Audet, S., Beeler, J.A., 2000. The fusion glycoprotein of human
respiratory syncytial virus facilitates virus attachment and infectivity via an
interaction with cellular heparan sulfate. J. Virol. 74 (14), 6442–6447.
Gassen, U., Collins, F.M., Duprex, W.P., Rima, B.K., 2000. Establishment of a
rescue system for canine distemper virus. J. Virol. 74 (22), 10737–10744.
Gemma, T.,Watari, T., Akiyama, K., Miyashita, N., Shin, Y.S., Iwatsuki, K., Kai,
C., Mikami, T., 1996. Epidemiological observations on recent outbreaks of
canine distemper in Tokyo area. J. Vet. Med. Sci. 58 (6), 547–550.
Grachev, M.A., Kumarev, V.P., Mamaev, L.V., Zorin, V.L., Baranova, L.V.,
Denikina, N.N., Belikov, S.I., Petrov, E.A., Kolesnik, V.S., Kolesnik, R.S.,
Dorofeev, V.M., Beim, A.M., Kudelin, V.N., Nagieva, F.G., Sidorv, V.N.,
1989. Distemper virus in Baikal seals. Nature 338 (6212), 209–210.
Hallak, L.K., Collins, P.L., Knudson, W., Peeples, M.E., 2000. Iduronic acid-
containing glycosaminoglycans on target cells are required for efficient
respiratory syncytial virus infection. Virology 271 (2), 264–275.
Hashimoto, K., Ono, N., Tatsuo, H., Minagawa, H., Takeda, M., Takeuchi, K.,
Yanagi, Y., 2002. SLAM (CD150)-independent measles virus entry as
revealed by recombinant virus expressing green fluorescent protein. J. Virol.
76 (13), 6743–6749.
Hirayama, N., Senda, M., Nakashima, N., Takagi, M., Sugiyama, M.,
Yoshikawa, Y., Yamanouchi, K., 1991. Protective effects of monoclonal
antibodies against lethal canine distemper virus infection in mice. J. Gen.
Virol. 72 (Pt. 11), 2827–2830.
Horvath, C.M., 2004. Silencing STATs: lessons from paramyxovirus interferon
evasion. Cytokine Growth Factor Rev. 15 (2–3), 117–127.
Ishida, H., Ayata, M., Shingai, M., Matsunaga, I., Seto, Y., Katayama, Y., Iritani,
N., Seya, T., Yanagi, Y., Matsuoka, O., Yamano, T., Ogura, H., 2004.
Infection of different cell lines of neural origin with subacute sclerosing
panencephalitis (SSPE) virus. Microbiol. Immunol. 48 (4), 277–287.
Jackson, R.L., Busch, S.J., Cardin, A.D., 1991. Glycosaminoglycans: molecular
properties, protein interactions, and role in physiological processes. Physiol.
Rev. 71 (2), 481–539.
Jackson, T., Ellard, F.M., Ghazaleh, R.A., Brookes, S.M., Blakemore, W.E.,
Corteyn, A.H., Stuart, D.I., Newman, J.W., King, A.M., 1996. Efficient
infection of cells in culture by type O foot-and-mouth disease virus requires
binding to cell surface heparan sulfate. J. Virol. 70 (8), 5282–5287.
Kai, C., Ochikubo, F., Okita, M., Iinuma, T., Mikami, T., Kobune, F.,
335K. Fujita et al. / Virology 359 (2007) 324–335Yamanouchi, K., 1993. Use of B95a cells for isolation of canine distemper
virus from clinical cases. J. Vet. Med. Sci. 55 (6), 1067–1070.
Kai, C., Miura, R., Fujita, K., Shimizu, F., Sato, H., Wakasa, C., Uema, M.,
2000. 11th Int. Conf. NSV.
Karger, A., Schmidt, U., Buchholz, U.J., 2001. Recombinant bovine respiratory
syncytial virus with deletions of the G or SH genes: G and F proteins bind
heparin. J. Gen. Virol. 82 (3), 631–640.
Kjellen, L., Lindahl, U., 1991. Proteoglycans: structures and interactions. Annu.
Rev. Biochem. 60, 443–475.
Klimstra, W.B., Ryman, K.D., Johnston, R.E., 1998. Adaptation of Sindbis virus
to BHK cells selects for use of heparan sulfate as an attachment receptor. J.
Virol. 72 (9), 7357–7366.
Kobune, F., Sakata, H., Sugiura, A., 1990. Marmoset lymphoblastoid cells as a
sensitive host for isolation of measles virus. J. Virol. 64 (2), 700–705.
Krusat, T., Streckert, H.J., 1997. Heparin-dependent attachment of respiratory
syncytial virus (RSV) to host cells. Arch. Virol. 142 (6), 1247–1254.
Lan, N.T., Yamaguchi, R., Kai, K., Uchida, K., Kato, A., Tateyama, S., 2005.
The growth profiles of three types of canine distemper virus on Vero cells
expressing canine signaling lymphocyte activation molecule. J. Vet. Med.
Sci. 67 (5), 491–495.
Loffler, S., Lottspeich, F., Lanza, F., Azorsa, D.O., ter Meulen, V., Schneider-
Schaulies, J., 1997. CD9, a tetraspan transmembrane protein, renders cells
susceptible to canine distemper virus. J. Virol. 71 (1), 42–49.
Maes, R.K., Wise, A.G., Fitzgerald, S.D., Ramudo, A., Kline, J., Vilnis, A.,
Benson, C., 2003. A canine distemper outbreak in Alaska: diagnosis and
strain characterization using sequence analysis. J. Vet. Diagn. Invest. 15 (3),
213–220.
Mandl, C.W.,Kroschewski,H., Allison, S.L., Kofler, R., Holzmann,H.,Meixner,
T., Heinz, F.X., 2001. Adaptation of tick-borne encephalitis virus to BHK-21
cells results in the formation of multiple heparan sulfate binding sites in the
envelope protein and attenuation in vivo. J. Virol. 75 (12), 5627–5637.
Nielsen, L., Andersen, M.K., Jensen, T.D., Blixenkrone-Moller, M., Bolt, G.,
2003. Changes in the receptor binding haemagglutinin protein of wild-type
morbilliviruses are not required for adaptation to Vero cells. Virus Genes 27
(2), 157–162.
Niwa, H., Yamamura, K., Miyazaki, J., 1991. Efficient selection for high-
expression transfectants with a novel eukaryotic vector. Gene 108 (2),
193–199.
Parks, C.L., Wang, H.P., Kovacs, G.R., Vasilakis, N., Kowalski, J., Nowak, R.
M., Lerch, R.A., Walpita, P., Sidhu, M.S., Udem, S.A., 2002. Expression of
a foreign gene by recombinant canine distemper virus recovered from cloned
DNAs. Virus Res. 83 (1–2), 131–147.
Patel, M., Yanagishita, M., Roderiquez, G., Bou-Habib, D.C., Oravecz, T.,
Hascall, V.C., Norcross, M.A., 1993. Cell-surface heparan sulfate
proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum.
Retroviruses 9 (2), 167–174.
Patterson, J.B., Thomas, D., Lewicki, H., Billeter, M.A., Oldstone, M.B., 2000.
V and C proteins of measles virus function as virulence factors in vivo.
Virology 267 (1), 80–89.Plattet, P., Zweifel, C., Wiederkehr, C., Belloy, L., Cherpillod, P., Zurbriggen,
A., Wittek, R., 2004. Recovery of a persistent Canine distemper virus
expressing the enhanced green fluorescent protein from cloned cDNA. Virus
Res. 101 (2), 147–153.
Roelke-Parker, M.E., Munson, L., Packer, C., Kock, R., Cleaveland, S.,
Carpenter, M., O'Brien, S.J., Pospischil, A., Hofmann-Lehmann, R., Lutz,
H., 1996. A canine distemper virus epidemic in Serengeti lions (Panthera
leo). Nature 379 (6564), 441–445.
Rostand, K.S., Esko, J.D., 1997. Microbial adherence to and invasion through
proteoglycans. Infect. Immunol. 65 (1), 1–8.
Sa-Carvalho, D., Rieder, E., Baxt, B., Rodarte, R., Tanuri, A., Mason, P.W.,
1997. Tissue culture adaptation of foot-and-mouth disease virus selects
viruses that bind to heparin and are attenuated in cattle. J. Virol. 71 (7),
5115–5123.
Seki, F., Ono, N., Yamaguchi, R., Yanagi, Y., 2003. Efficient isolation of wild
strains of canine distemper virus in Vero cells expressing canine SLAM
(CD150) and their adaptability to marmoset B95a cells. J. Virol. 77 (18),
9943–9950.
Shingai, M., Ayata, M., Ishida, H., Matsunaga, I., Katayama, Y., Seya, T.,
Tatsuo, H., Yanagi, Y., Ogura, H., 2003. Receptor use by vesicular stomatitis
virus pseudotypes with glycoproteins of defective variants of measles virus
isolated from brains of patients with subacute sclerosing panencephalitis.
J. Gen. Virol. 84 (Pt. 8), 2133–2143.
Summerford, C., Samulski, R.J., 1998. Membrane-associated heparan sulfate
proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol.
72 (2), 1438–1445.
Takeuchi, K., Miyajima, N., Nagata, N., Takeda, M., Tashiro, M., 2003. Wild-
type measles virus induces large syncytium formation in primary human
small airway epithelial cells by a SLAM(CD150)-independent mechanism.
Virus Res. 94 (1), 11–16.
Tatsuo, H., Ono, N., Tanaka, K., Yanagi, Y., 2000. SLAM (CDw150)
is a cellular receptor for measles virus. Nature 406 (6798),
893–897.
Tatsuo, H., Ono, N., Yanagi, Y., 2001. Morbilliviruses use signaling lymphocyte
activation molecules (CD150) as cellular receptors. J. Virol. 75 (13),
5842–5850.
Tober, C., Seufert, M., Schneider, H., Billeter, M.A., Johnston, I.C., Niewiesk,
S., ter Meulen, V., Schneider-Schaulies, S., 1998. Expression of measles
virus V protein is associated with pathogenicity and control of viral RNA
synthesis. J. Virol. 72 (10), 8124–8132.
von Messling, V., Zimmer, G., Herrler, G., Haas, L., Cattaneo, R., 2001. The
hemagglutinin of canine distemper virus determines tropism and cytopatho-
genicity. J. Virol. 75 (14), 6418–6427.
von Messling, V., Svitek, N., Cattaneo, R., 2006. Receptor (SLAM [CD150])
recognition and the V protein sustain swift lymphocyte-based invasion of
mucosal tissue and lymphatic organs by a morbillivirus. J. Virol. 80 (12),
6084–6092.
WuDunn, D., Spear, P.G., 1989. Initial interaction of herpes simplex virus with
cells is binding to heparan sulfate. J. Virol. 63 (1), 52–58.
